B. L. Pentecost

Immunoglobulin response to intravenous streptokinase in acute myocardial infarction.

OBJECTIVE--To devise assays to assess and follow the specific antibody response in patients treated with streptokinase for acute myocardial infarction. DESIGN--Venous blood samples were collected before treatment with streptokinase started and subsequently at regular intervals over one year. Specific IgG and subclass IgG1 were assessed by an enzyme linked immunosorbent assay. SETTING--Coronary care unit in a general hospital. PATIENTS--48 patients with acute myocardial infarction: 22 patients had venous blood samples taken at presentation only; serial blood samples were taken from 20 patients who then received thrombolytic therapy with streptokinase and six patients who were unsuitable for thrombolytic therapy. RESULTS--Titres of antibodies to streptokinase were low at presentation in 36 (75%) of the 48 patients. Serial measurements made in 20 patients showed the virtual disappearance of antibody within the first 24 hours. This was followed by a steady increase in the specific IgG1 titre, which peaked at day 14 before gradually declining. Values at one year remained significantly higher than baseline values. There was no evidence of an IgM response in the patients studied. CONCLUSION--Low titres of antibodies to streptokinase were widespread in the population. Antibody was consumed after treatment and the subsequent immunoglobulin rise suggested a secondary immune responses; the recently described neutralising capacity to streptokinase is probably related to this antibody.

EFFECT OF GL ENZYME (A HIGHLY PURIFIED FORM OF HYALURONIDASE) ON MORTALITY AFTER MYOCARDIAL INFARCTION

The influence of intravenous GL enzyme (hyaluronidase) on the outcome of myocardial infarction was assessed in a controlled trial among 483 patients presenting within 6 h of the onset of symptoms. There was a consistent trend towards reduced mortality throughout the period of follow-up among GL enzyme treated patients. When the fate of all patients entering the trial was considered, irrespective of final diagnosis, the reduction in mortality at 6 months (27 of 240 GL enzyme patients, 45 of 243 placebo) was statistically significant (p = 0.025).

Reappraisal of lignocaine therapy in management of myocardial infarction.

The use of lignocaine in the prevention of ventricular fibrillation among patients admitted to a coronary care unit has been reviewed over the 12-year period 1967 to 1978 inclusive. The practice of suppressing warning ventricular ectopic activity has gradually been abandoned with the result that whereas in 1967 to 1968 33 per cent of all patients received lignocaine therapy, in 1972 to 1973 the number had fallen to 15 per cent, and in 1977 to 1978 to 4 per cent. The incidence of ventricular fibrillation was not significantly changed at 9.1, 7.7, and 7.8 per cent, respectively. Approximately 80 per cent of all patients suffering ventricular fibrillation within the coronary care unit were initially resuscitated and approximately 50 per cent survived hospital admission. Death was rarely a result of recurrent ventricular fibrillation and for the most part took the form of pump failure or late unexpected death. Experience suggests that the use of lignocaine to suppress ventricular ectopic activity observed in the first few hours of admission to hospital with acute myocardial infarction has no therapeutic value.

The Birmingham blood pressure school study.

Four-hundred and twenty-eight school leavers of 3 ethnic groups (white, black and Asian) were screened for blood pressure, resting pulse rate and general anthropometric characteristics. Asian pupils were both shorter and lighter than the other two groups whilst black males were heavier and taller. There was no significant difference in the mean systolic or diastolic blood pressure between the 3 groups, although the black pupils had a stronger family history of hypertension, particularly on the mothers side. These observations differ in some respects from other ethnic blood pressure studies and establish values for the local population.

The distribution of antibodies to streptokinase.

To determine the distribution of antibodies to streptokinase that might be anticipated in patients requiring treatment with streptokinase, specific anti-streptokinase antibody titres were determined in a group of subjects from the general population and in a group of patients presenting with acute myocardial infarction. Enzyme-linked immunosorbent assays were developed to measure specific anti-streptokinase IgG and subclass IgG1 in 95 subjects from the general population and in 160 patients presenting with acute myocardial infarction. Low titres of IgG1 were found in both the general population (median = 5; range: 0-490) and in the myocardial infarction group (median = 7; range: 0-2000). A minority of subjects in both groups had high titres. The findings suggest that low titres of antibody are widespread in the population. The minority of subjects in both groups who had high titres may explain the infrequent type III immune reactions encountered with streptokinase.

Influence of racial origin on admission rates of patients with suspected myocardial infarction in Birmingham.

All patients with suspected myocardial infarction admitted to hospital in four Birmingham health districts were studied to test the hypothesis that Asian patients would be overrepresented and Caribbean patients underrepresented compared with the indigenous population. One thousand four hundred and ninety six patients had a final diagnosis of myocardial infarction or severe angina pectoris. The relative risk of admission for Asian men compared with white men aged 45-64 years was 2.65 (95% confidence interval 2.20 to 3.19) and the risk for Asian men was high for both myocardial infarction and ischaemia when analysed separately. The relative risk of admission for Caribbean men compared with white men was 0.53 (95% CI 0.33 to 1.20). The relative risk for Asian women compared with white women in the same age group was 2.58 (95% CI 1.68 to 3.96), but this was due to an excess of admissions diagnosed as ischaemia rather than infarction in the Asian women. For Caribbean and white women the risk of admission was the same, although significantly fewer Caribbean women were admitted with myocardial infarction. The study was undertaken in 1986-87 and population data had to be derived from the 1981 census. The resident population changed in those five years and so the results were recalculated making allowances for these changes in the health districts involved. Based on these data the admission rate for Asian men with suspected myocardial infarction aged 45-64 was nearly twice that for white men (1.8): the relative risk of admission for Asian men compared with white men was 2.04 (95% CI 1.53 to 2.18). For Caribbean men the relative risk compared with white men was 0.45 (95% CI 0.29 to 0.71). For Asian women the relative risk of admission calculated from the adjusted census data resemble that in white women aged 45-64 years. The relative risk for admission with coronary heart disease in Asians is higher than expected work; one possible explanation for this is that the Asian population resident in the area under study was larger than estimated. The single major difference in risk factors was the high prevalence of diabetes mellitus in Asians (19.5% compared with 8.3% for white residents) but this did not wholly account for the excess of admissions from the Asian community.

The birmingham trial of permanent pacing in patients with intraventricular conduction disorders after acute myocardial infarction

Patients surviving 2 weeks after myocardial infarction who had persistent conduction disorder (right bundle branch block alone or associated with left anterior or posterior hemiblock [LPH] or LPH alone) were allocated at random to permanent pacing or control groups. Throughout follow-up, up to 5 years, there was no significant difference in survival: at 2 years 14 of 23 (61%) of paced patients had died compared with 11 of 27 (41%) control patients. Progression of conduction disorder was not observed and measurement of infranodal conduction time (HV interval) did not predict outcome. Ventricular tachyarrhythmias were an important cause of death in these patients and pacing appears to offer no benefit.

Overt and Subclinical Reactions to Streptokinase in Acute Myocardial Infarction

The aims of this study were (1) to assess the possibility of predicting allergic reactions to streptokinase (SK) by measuring pretreatment antibody titers and by intradermal skin testing, and (2) to determine if SK is associated with subclinical changes in renal function. Specific anti-SK immunoglobulin G (IgG) and subclass IgG1 were assessed by enzyme-linked immunosorbent sorbent assays, and renal function was assessed by measurement of serum urea and creatinine in 204 patients with acute myocardial infarction. Twenty-six patients had 24-hour proteinuria loss and creatinine clearance assessed at presentation. Median IgG titer at presentation was 6 (range 0 to 10,000), and increased to 60 (range 0 to 18,000; p < 0.0001) on day 6. Fifteen of 180 patients (8.3%) had minor allergic reactions to SK; the median titer on admission for these patients was 5 (range 0 to 60), identical to those who tolerated SK uneventfully. No change was seen in serum urea or creatinine; for those treated with SK, the median value for proteinuria loss at day 0 was 0.45 g/liter (range 0.1 to 2), and decreased by day 5 to 0.1 g/liter (range 0.1 to 0.8; p = 0.0027). No significant proteinuria was seen in those who did not receive SK. The reactions to SK were minor, and could not be predicted on the basis of IgG titers at presentation. Significant proteinuria was found in the first 24 hours in SK-treated patients, but not in those who did not receive SK, and it resolved by day 5.

Streptokinase resistance: when might streptokinase administration be ineffective?

4 Silove ED, Abrams LD, Brawn WJ, De Giovanni JV, Sethia B, Wright JGC. Continued treatment with prostaglandins after pulmonary valvotomy for pulmonary atresia with intact ventricular septum [abstr] Br Heart J 1990;64: 103. 5 Amodeo A, Keeton BR, Sutherland GR, Monro JL. Pulmonary atresia with intact ventricular septum: is neonatal repair advisable? EurJ Cardiothorac Surg 199 1;5: 17-21. 6 Coles JG, Freedom RM, Lightfoot NE, Dasmahapatra HK, Williams WG, Trusler GA, Burrows PE. Long-term results in neonates with pulmonary atresia and intact ventricular septum. Ann Thorac Surg 1989; 47:213-7. 7 Cabezuelo Huerta G, Frontera Izquierdo P. Mortality and survival rate in pulmonary atresia with intact intraventricular septum. Determining factors. An Esp Pediatr 1990; 32:33-6. 8 Hawkins JA, Thorne JK, Boucek MM, Orsmond GS, Ruttenberg HD, Veasy LG, McGough EC. Early and late results in pulmonary atresia and intact ventricular septum. J Thorac Cardiovasc Surg 1990; 100:492-7. 9 Beitzke A, Rigler B, Stein JI, Suppan CH. Early and late results in the treatment of patients with pulmonary atresia and intact ventricular septum [abstr]. Pediatr Cardiol 1990;11:234. 10. Hartyanszky IL, Kadar K, Faller K, Lozsadi K. Surgical management of pulmonary atresia with intact ventricular septum. Right ventricular size as a guideline for surgical intervention. Acta Paediatr Hung 1991;31: 443-56. 11 Leung MP, Lo RN, Cheung H, Lee J, Mok *CK. Balloon valvuloplasty after pulmonary valvotomy for babies with pulmonary atresia and intact ventricular septum. Ann Thorac Surg 1992;53:864-70. 12 Niederhuser U, Bauer EP, von Segesser LK, Carrel T, Laske A, Schonbeck M, Turina M. Pulmonary atresia with intact ventricular septum: results and predictive factors of surgical treatment. Thorac Cardiovasc Surg 1992;40: 130-4. 13 Steinberger J, Berry JM, Bass JL, Foker JE, Braunlin EA, Krabill KA, Rocchini AP. Results of a right ventricular outflow patch for pulmonary atresia with intact ventricular septum. Circulation 1992;86(suppl II): 167-75. 14 Norwood WI. Hypoplastic left heart syndrome. Ann Thorac Surg 1991;52:688-95.